Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutathione reductase from Plasmodium falciparum (PfGR) is a homodimeric flavoenzyme central to the parasite's antioxidant defense, catalyzing the NADPH-dependent reduction of oxidized glutathione (GSSG) to reduced glutathione (GSH). This maintains redox balance, allowing the parasite to withstand oxidative stress encountered in the host. Its structural divergence from the human enzyme—especially at the ligand-binding and intersubunit sites—makes PfGR an attractive target for antimalarial therapy. Selective inhibition impairs the parasite's ability to detoxify reactive oxygen species, contributing to parasite death[1][2][3][6][7].
Inhibition of glutathione reductase disrupts reduction of glutathione disulfide (GSSG) to reduced glutathione (GSH), impairing the parasite's antioxidant defenses[2][3][7].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutathione reductase (Plasmodium falciparum) (PfGR).